Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Einarson, T. R.
Right arrow Articles by Doyle, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Einarson, T. R.
Right arrow Articles by Doyle, J. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Rank-order Stability Analysis (ROSA)

Testing Pharmacoeconomic Data

Thomas R. Einarson, PhD

Steven R. Arikian, MD

John J. Doyle

In a pharmacoeconomic analysis, the validity of findings is critical because product ranking may influence formulary decision making. The authors present an approach for examining uncertainty in a pharmacoeconomic analysis that parallels the confidence-interval approach to statistical analysis. This method, rank-order stability analysis (ROSA), is a clear and comprehensive method for validating results of a pharmacoeconomic analysis, as it identifies and evaluates all inputs and values. It is a break-even analysis that identifies the specific point of insensitivity for all parameters analyzed in the pharmacoeconomic model. ROSA is proposed as the preferred method for judging the validity of results derived from estimated parameters in pharmacoeconomic analyses. Key words: pharmacoeconomic analysis; sen sitivity analysis; robustness; cost-effectiveness analysis; rank-order stability analysis. (Med Decis Making 1995;15:367-372)

Medical Decision Making, Vol. 15, No. 4, 367-372 (1995)
DOI: 10.1177/0272989X9501500407
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?